{
  "abstract": "Pancreatic cancer remains one of the most lethal malignancies with limited therapeutic options. This study investigates the anti-cancer effects of eriodyctiol, a natural flavonoid, and its potential as combination therapy with gemcitabine in pancreatic cancer treatment. Molecular docking analysis indicated eriodyctiol-P53 interactions. Pancreatic cancer cells BxPC-3 and Capan-2 were treated with eriodyctiol, and effects were assessed using Cell Counting Kit-8 (CCK-8) viability assays, Western blot, immunofluorescence, co-immunoprecipitation (Co-IP), cellular thermal shift assay (CETSA), flow cytometry, and quantitative real-time polymerase chain reaction (qRT-PCR). Synergistic effects with gemcitabine were evaluated in vitro and validated in xenograft mouse models. Eriodyctiol demonstrated dose-dependent cytotoxicity in BxPC-3 and Capan-2 cells. Treatment enhanced P53 protein stability and nuclear translocation, upregulated downstream targets p21, BAX, and PUMA, and increased apoptosis. CETSA confirmed direct eriodyctiol-P53 binding, and Co-IP assay revealed the disruption of MDM2-P53 interaction by eriodyctiol treatment. Rescue experiments confirmed P53-dependent, caspase-3-mediated apoptosis induced by eriodyctiol. Importantly, combination with gemcitabine showed strong synergistic effects in vitro and enhanced anti-tumor efficacy in vivo. Eriodyctiol exhibits potent anti-cancer activity through P53 binding and MDM2-P53 interaction disruption, leading to P53-dependent apoptosis. The compound shows promise as a novel therapeutic strategy that synergistically enhances gemcitabine efficacy in pancreatic cancer treatment.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Gastroenterology, Guizhou Medical University Affiliated Cancer Hospital, Guiyang, China.",
    "Department of Gastroenterology, Guiyang Hospital of Guizhou Aviation Company, Guiyang, China.",
    "Department of Hematology and Oncology, The First People's Hospital of Guiyang, Guiyang, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zhe Liu"
    },
    {
      "affs": [
        1
      ],
      "name": "Long Yang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiaorong Zhu"
    },
    {
      "affs": [
        0
      ],
      "name": "Ting Dai"
    },
    {
      "affs": [
        0
      ],
      "name": "Lihui Cheng"
    },
    {
      "affs": [
        2
      ],
      "name": "Xiaoyan Hu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6s1fd7v0ks48g.bib",
  "cited_by": 0,
  "doi": "10.21037/tcr-2026-1541",
  "fulltext_url": "https://europepmc.org/articles/PMC13743216",
  "id": "6s1fd7v0ks48g",
  "issns": [
    "2218-676X",
    "2219-6803"
  ],
  "landing_url": "https://europepmc.org/article/MED/42997689",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Cancer-related Molecular Pathways"
    ]
  ],
  "openalex": "W7224095188",
  "pdf_url": "https://europepmc.org/articles/PMC13743216?pdf=render",
  "pmcid": "PMC13743216",
  "pmid": "42997689",
  "published": "2026-09-28",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/6s1fd7v0ks48g.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T15:20:41Z",
      "native_id": "MED:42997689",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42997689"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer-related Molecular Pathways",
      "subfield": "oncology"
    }
  ],
  "title": "Eriodyctiol induces P53-dependent apoptosis in pancreatic cancer through disruption of MDM2-P53 interaction and synergistically enhances gemcitabine efficacy.",
  "title_text": "Eriodyctiol induces P53-dependent apoptosis in pancreatic cancer through disruption of MDM2-P53 interaction and synergistically enhances gemcitabine efficacy.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T15:20:41Z",
  "url": "https://research.draconitic.com/paper/6s1fd7v0ks48g",
  "venue": "Translational cancer research",
  "versions": []
}